Kura Oncology, Inc.
DE ˙ DB ˙ US50127T1097
7,56 € ↑0,24 (3,28%)
2026-06-05
DELAT PRIS
SecurityDE:KUR / Kura Oncology, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership4,931,090 shares
Ownership 5.70%
State Street Corp ownership in KUR / Kura Oncology, Inc.

2026-02-09 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,931,090 shares of Kura Oncology, Inc. (DE:KUR). This represents 5.7 percent ownership of the company. In their previous filing dated 2024-01-23 , State Street Corp had reported owning 2,921,810 shares, indicating an increase of 68.77 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-02-09 2026-02-09 13G 2,921,810 4,931,090 68.77 5.70 45.04
2024-01-23 2024-01-23 13G/A 4,446,427 2,921,810 -34.29 3.93 -40.90
2023-02-03 2023-02-03 13G/A 3,378,143 4,446,427 31.62 6.65 30.91
2022-02-11 2022-02-11 13G 3,378,143 5.08

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F KURA ONCOLOGY COM 50127T109 4,511,891 -419,199 -8.50 36,682 -28.40 0.0013
2026-02-13 2025-12-31 13F KURA ONCOLOGY COM 50127T109 4,931,090 1,587,959 47.50 51,234 73.17 0.0017
2025-11-14 2025-09-30 13F KURA ONCOLOGY COM 50127T109 3,343,131 306,273 10.09 29,587 68.85 0.0010
2025-08-14 2025-06-30 13F KURA ONCOLOGY COM 50127T109 3,036,858 -245,222 -7.47 17,523 -19.11 0.0007
2025-05-15 2025-03-31 13F KURA ONCOLOGY COM 50127T109 3,282,080 -63,382 -1.89 21,662 -25.66 0.0009
2025-02-14 2024-12-31 13F KURA ONCOLOGY COM 50127T109 3,345,462 676,618 25.35 29,139 -44.13 0.0011
2024-11-14 2024-09-30 13F KURA ONCOLOGY COM 50127T109 2,668,844 -215,697 -7.48 52,149 -12.20 0.0021
2024-08-14 2024-06-30 13F KURA ONCOLOGY COM 50127T109 2,884,541 -1,315,413 -31.32 59,393 -33.70 0.0026
2024-05-15 2024-03-31 13F KURA ONCOLOGY COM 50127T109 4,199,954 1,278,144 43.74 89,585 113.22 0.0040
2024-02-14 2023-12-31 13F KURA ONCOLOGY COM 50127T109 2,921,810 -334,777 -10.28 42,016 41.46 0.0020
2023-11-14 2023-09-30 13F KURA ONCOLOGY COM 50127T109 3,256,587 243,439 8.08 29,700 -6.84 0.0016
2023-08-14 2023-06-30 13F KURA ONCOLOGY COM 50127T109 3,013,148 -829,530 -21.59 31,879 -32.17 0.0017
2023-05-15 2023-03-31 13F KURA ONCOLOGY COM 50127T109 3,842,678 -603,749 -13.58 46,996 -14.83 0.0027
2023-05-15 2022-12-31 13F/A-99 KURA ONCOLOGY COM 50127T109 4,446,427 77,664 1.78 55,180 -7.54 0.0032
2023-05-15 2022-12-31 13F KURA ONCOLOGY COM 50127T109 4,446,427 77,664 55,180 0.0032
2022-11-15 2022-09-30 13F KURA ONCOLOGY COM 50127T109 4,368,763 1,337,149 44.11 59,677 7.39 0.0038
2022-08-15 2022-06-30 13F KURA ONCOLOGY COM 50127T109 3,031,614 -269,134 -8.15 55,569 4.70 0.0033
2022-05-16 2022-03-31 13F KURA ONCOLOGY COM 50127T109 3,300,748 -77,395 -2.29 53,076 12.23 0.0026
2022-02-14 2021-12-31 13F KURA ONCOLOGY COM 50127T109 3,378,143 169,034 5.27 47,294 -21.32 0.0022
2021-11-15 2021-09-30 13F KURA ONCOLOGY COM 50127T109 3,209,109 -45,533 -1.40 60,107 -11.42 0.0032
2021-08-16 2021-06-30 13F KURA ONCOLOGY COM 50127T109 3,254,642 420,992 14.86 67,859 -15.29 0.0036
2021-07-09 2021-03-31 13F/A-1 KURA ONCOLOGY COM 50127T109 2,833,650 156,430 5.84 80,107 -8.38 0.0046
2021-05-17 2021-03-31 13F KURA ONCOLOGY COM 50127T109 2,833,650 156,430 80,107 0.0046
2021-02-16 2020-12-31 13F KURA ONCOLOGY COM 50127T109 2,677,220 946,021 54.65 87,438 64.84 0.0054
2020-11-10 2020-09-30 13F KURA ONCOLOGY COM 50127T109 1,731,199 77,498 4.69 53,044 96.79 0.0036
2020-08-14 2020-06-30 13F KURA ONCOLOGY COM 50127T109 1,653,701 569,974 52.59 26,955 149.98 0.0020
2020-06-19 2020-03-31 13F/A-1 KURA ONCOLOGY COM 50127T109 1,083,727 23,444 2.21 10,783 -26.04 0.0009
2020-05-11 2020-03-31 13F KURA ONCOLOGY COM 50127T109 1,083,727 23,444 10,783 946.9645
2020-02-06 2019-12-31 13F KURA ONCOLOGY COM 50127T109 1,060,283 -166,245 -13.55 14,579 -21.64 0.0010
2019-11-14 2019-09-30 13F KURA ONCOLOGY COM 50127T109 1,226,528 419,582 52.00 18,606 17.10 0.0014
2019-08-14 2019-06-30 13F KURA ONCOLOGY COM 50127T109 806,946 -136,891 -14.50 15,889 1.48 0.0012
2019-05-15 2019-03-31 13F KURA ONCOLOGY COM 50127T109 943,837 70,211 8.04 15,658 27.65 0.0012
2019-02-12 2018-12-31 13F KURA ONCOLOGY COM 50127T109 873,626 -296,720 -25.35 12,266 -40.12 0.0011
2018-11-09 2018-09-30 13F KURA ONCOLOGY Common equity shares 50127T109 1,170,346 135,165 13.06 20,484 8.73 0.0016
2018-08-14 2018-06-30 13F KURA ONCOLOGY Common equity shares 50127T109 1,035,181 256,297 32.91 18,840 29.01 0.0016
2018-05-15 2018-03-31 13F KURA ONCOLOGY Common equity shares 50127T109 778,884 490,758 170.33 14,603 231.06 0.0012
2018-02-14 2017-12-31 13F KURA ONCOLOGY Common equity shares 50127T109 288,126 46,248 19.12 4,411 22.12 0.0004
2017-11-14 2017-09-30 13F KURA ONCOLOGY Common equity shares 50127T109 241,878 92,129 61.52 3,612 159.11 0.0003
2017-08-14 2017-06-30 13F KURA ONCOLOGY Common equity shares 50127T109 149,749 149,749 1,394 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.